Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 1.00 |
| ▸ | HTR2B | P41595 | 15/20 | 1.00 |
| ▸ | HTR2A | P28223 | 18/20 | 0.71 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097006 | 1.00 | HTR2C (1.00) | HTR2CHTR2BHTR2ADRD1DRD5 | |
| SCHEMBL1095210 | 1.00 | HTR2C (1.00) | HTR2CHTR2BHTR2ADRD1DRD5 | |
| SCHEMBL13673035 | 0.84 | HTR2C (0.72) | HTR2CHTR2BHTR2ADRD1DRD5 | |
| SCHEMBL1094962 | 0.83 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL1094963 | 0.83 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL1094326 | 0.83 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL1095399 | 0.82 | HTR2C (0.69) | HTR2CHTR2BHTR2ADRD1DRD5 | |
| SCHEMBL1901752 | 0.82 | HTR2C (0.69) | HTR2CHTR2BHTR2ADRD1DRD5 | |
| SCHEMBL1095400 | 0.82 | HTR2C (0.69) | HTR2CHTR2BHTR2ADRD1DRD5 | |
| SCHEMBL1908446 | 0.82 | HTR2C (0.76) | HTR2CHTR2BHTR2ADRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546379-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8153621-B2 | phentermine and a selective 5HT-2C receptor agonist such as lorcaserin; decrease food intake | ARENA PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2374796-A1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders | Arena Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2363394-A1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders | Arena Pharmaceuticals, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7977329-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2322162-A1 | 5HT2C receptor modulator compositions and methods of use | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7514422-B2 | 5HT2c receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20030225057-A1 | 3-Benzoazepine derivatives | ARENA PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225057-A1 | 3-Benzoazepine derivatives | HTR2C, HTR1A, HTR3A | HTR2C 1/4885HTR2B 10/4885HTR2A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.